Gene Solutions, a multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company focused on democratizing access to life science tools, have formalized a strategic collaboration through a Memorandum of Understanding (MoU). The agreement was signed during Element Biosciences' visit to Gene Solutions' laboratory.
The collaboration aims to create significant synergies by integrating Element Biosciences' next-generation sequencing (NGS) platforms with Gene Solutions' innovative genetic testing technologies. This partnership is expected to enhance genomics research capabilities and expand market accessibility for both companies globally.
Expanding Access to Reproductive Health Technologies
Non-invasive prenatal testing (NIPT) represents one of the most widely adopted clinical applications of NGS technology worldwide. The test analyzes cell-free DNA fragments from the placenta in maternal blood to screen for genomic abnormalities and is recommended for pregnant women from 9-10 weeks of gestation.
Gene Solutions has built a comprehensive reproductive health ecosystem over the past eight years, centered around its triSure™ NIPT portfolio. The company has developed a unique integrated workflow that combines screening for recessive diseases and dominant single-gene disorders with NIPT, powered by artificial intelligence and optimized laboratory protocols.
"Our foundation is in the research and development of genetic solutions," said Dr. Nguyen Huu Nguyen, Deputy CEO of Gene Solutions. "By combining Element Biosciences' powerful platform with Gene Solutions' expertise and market reach, we are confident that we can significantly enhance the accessibility and application of genomic advances."
The NIPT market, valued at USD 5.20 billion in 2022, is projected to reach USD 19.09 billion by 2030. Through this collaboration, Gene Solutions aims to leverage Element's accessible and affordable research solutions to bring safe, accurate, and non-invasive screening tools to pregnant women globally.
Advancing Precision Oncology Through Multiomics
Early cancer detection remains a critical challenge in oncology. Gene Solutions has commercialized its AI-powered SPOT-MAS test, which has demonstrated efficacy in identifying cancers at early stages, particularly those lacking established screening methods.
For cancer patients, the company offers tailored solutions for selecting targeted therapies and immunotherapies by uniquely combining genomic and transcriptomic tumor profiling with personalized cancer monitoring through its K-TRACK and K-4CARE technologies.
The collaboration will accelerate research supporting the integration of Gene Solution's advanced cancer care tools into clinical practice globally, leveraging Element Biosciences' AVITI24™ multiomics platform. This first-of-its-kind platform delivers simultaneous in situ transcriptomic, proteomic, and morphological profiling at single-cell resolution through Teton™ kits and assays.
Powered by Element's proprietary avidite base chemistry (ABC) sequencing, AVITI24 provides researchers with a direct window into complex biological mechanisms and pathways. Gene Solutions plans to incorporate this technology into several research initiatives, including:
- Clinical Multi-omics Project
- 3D Patient-derived Organoids
- Neoantigen Cancer Vaccine pipeline
These initiatives represent Gene Solutions' approach to incorporating multi-modal AI and multi-omics insights to advance therapeutic development.
Global Impact and Market Reach
Gene Solutions currently serves over 4,500 hospitals and clinics across eight Asian countries, including Singapore, Vietnam, Thailand, Indonesia, Malaysia, the Philippines, Hong Kong, and Taiwan. The company operates a network of seven NGS laboratories, including two central CAP-accredited facilities in Singapore and Vietnam, and has provided over two million tests to patients since its establishment in 2017.
Edwin Hauw, Senior Vice President of Marketing & Product Management at Element Biosciences, highlighted the complementary nature of the partnership: "Our collaboration with Gene Solutions will combine the best of both our worlds: Element's revolutionary AVITI24 multiomics and AVITI sequencing platforms, and Gene Solutions expertise in bringing transformative genetic solutions to the APAC region. Together, we will elevate the research supporting the real-world impact these genetic testing solutions have downstream on patient outcomes."
Framework for Future Collaboration
The MoU establishes a framework for discussions on strategic partnerships, marketing efforts, customer-centric and technical support, and research and development opportunities. Both companies aim to leverage their respective expertise to enhance genomics research, clinical research applications, and market accessibility as part of their global strategies.
Element Biosciences has positioned itself as an innovator in the NGS field by developing solutions that provide exceptional performance and flexibility for researchers. The company's mission centers on democratizing access to advanced biological tools to drive impactful discoveries that benefit humanity.
This strategic collaboration represents a significant step toward expanding access to cutting-edge genetic testing technologies and precision medicine applications across global markets, potentially transforming patient care in reproductive health and oncology.
